Health
Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People
- Three-year study shows long-term benefits of obesity treatment
- Patients on highest dose lost 23% of body weight in 176 weeks
This article is for subscribers only.
Patients taking Eli Lilly & Co.’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity.
It’s the longest continuous study of Lilly’s drug Zepbound to date, the company said in a statement Tuesday. More than 1,000 patients with obesity and prediabetes were randomized to receive Lilly’s medicine or a placebo, and followed for just over three years.